Jounce Therapeutics — Investor Presentation (January 2019)
25 slides from Jounce Therapeutics's investor presentation, Jan 7, 2019
Slide 1: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Slide 2: Legal Disclaimer
Legal Disclaimer Various statements concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of research and development programs, preclinical studies and clinical trials for Jounce’s product candidat
Slide 3: Investment Highlights and Differentiation
Investment Highlights and Differentiation Advancing our Diverse Pipeline Robust Translational Science Platform • Three immunotherapies in the clinic in 2019 • Commitment to translational approach – JTX-2011 (ICOS) Phase 1/2 – New programs linked to immune cell composition – JTX-4014 (PD-1) Phase 1 i
Slide 4: Approach & IO Opportunity
DELIVERING VALUE PIPELINE EXECUTION APPROACH & IO OPPORTUNITY 4 | Jounce Therapeutics © January 2019
Slide 5: The Jounce Solution: Next Generation IO Will Require a Translational Approach
The Jounce Solution: Next Generation IO Will Require a Translational Approach Next Generation IO: Translational Science Innovative Pipeline What Will it Take? Platform • Identify the right patients • Biomarker driven approach Tumor Immune Infiltrate • Move beyond PD-1 centric • Rational, science-bas
Slide 6: Jounce Immunotherapy Pipeline
Jounce Immunotherapy Pipeline Development Programs Clinical Program Target Biology Preclinical Phase 1 Phase 2 Phase 3 CD4 T cell JTX-2011 ICOS focused CD8 T cell JTX-4014 PD-1 focused Suppressive JTX-8064 LILRB2 macrophage, colder tumor Research Programs Named Celgene Option Celgene Target Pool Tar
Slide 7: Development Programs: JTX-2011
Development Programs JTX-2011 JTX-8064 JTX-4014
Slide 8: JTX-2011 Mechanism: ICOS Agonist
JTX-2011 Mechanism: ICOS Agonist Clinical Evidence of Peripheral Agonism Activation of T effector cells APC APC IFN-Y IFN-Y st 1st signalICOS JTX-2011 TCR IFN-Y TCR IFN-Y TCR ICOS ↑ ICOS ICOS ↑IFN-γ “Non-Primed” “Primed” T effector cell T effector cell NK cell Selective reduction of T regulatory cel
Slide 9: JTX-2011: Key Learnings from Phase 1/2 ICONIC Trial
JTX-2011: Key Learnings from Phase 1/2 ICONIC Trial Safety • JTX-2011 safe and well tolerated alone and in combination with nivolumab Preliminary Efficacy* • All durable responses and tumor reductions associated with ICOS PD biomarker – RECIST PRs in PD-1i naïve patients – Tumor reductions in PD-1i
Slide 10: JTX-2011: Anti-Tumor Activity Correlates with Mechanistic Biomarker
JTX-2011: Anti-Tumor Activity Correlates with Mechanistic Biomarker ICOS hi CD4 Cells Emerge in Patients with Target Lesion Reductions* • Observed in 7/7 subjects with target lesion PR • Not observed in 12/12 subjects with target lesion progression Limited longitudinal samples for some subjects N= 4
Slide 11: The Importance of ICOS hi CD4 Cells
The Importance of ICOS hi CD4 Cells PD-1i Does Not Induce ICOS hi CD4 Cells JTX-2011 Amplifies an Immune Response Emergence of ICOS hi CD4 cells is due to JTX-2011 Only ICOS hi CD4 cells can be activated by JTX-2011 • 77 patients treated with PD-1i monotherapy 5 0 0 0 5 0 0 0 I N F y I N F y T N F a
Slide 12: JTX-2011: Reverse Translational Work Leads to Two Development Paths
JTX-2011: Reverse Translational Work Leads to Two Development Paths Predictive Biomarker CTLA-4i Combination Two Prioritize combination Development Identify baseline agents that induce Paths characteristics to predict which patients are able to ICOS hi CD4 cells induce ICOS hi CD4 cells Induction of
Slide 13: JTX-2011 Development Paths: New Phase Studies
JTX-2011 Development Paths: New Phase 2 Studies New Phase 2 JTX-2011 Upcoming Preliminary Efficacy Milestones New Schedules & Combination Sequences CTLA-4i • Initiate new Phase 2 studies PD-1i Experienced NSCLC • ICONIC data update – PFS and OS PD-1i Experienced Bladder – Further mechanistic and pre
Slide 14: JTX-2011: Opportunity in PD-1i Experienced NSCLC
JTX-2011: Opportunity in PD-1i Experienced NSCLC Patients with Driver Mutation Negative Stage IV NSCLC Rationale • Re-treatment of PD-1i failures with PD-1i 1L Platinum chemo PD-1i +/- chemo combinations has not addressed the unmet need • Tumor reductions observed in ICONIC PD-1i failure NSCLC patie
Slide 15: JTX-2011: Opportunities in PD-1i Experienced and Naïve Bladder Patients
JTX-2011: Opportunities in PD-1i Experienced and Naïve Bladder Patients Patients with Stage IV Bladder Cancer Rationale • PD-1i experienced: similar market 1L Cisplatin + gemcitabine Single-agent PD-1i or chemo (cisplatin-eligible) (cis/platinum ineligible) drivers as in NSCLC Unmet need in IO naïve
Slide 16: Development Programs: JTX-8064
Development Programs JTX-2011 JTX-8064 JTX-4014
Slide 17: Discovery Platform Relies on Human Immune Tumor Composition
Discovery Platform Relies on Human Immune Tumor Composition HOT T cells in the tumor COLD Macrophages in the tumor Potential single agent PD-1i Highest responders Unmet need 17 | Jounce Therapeutics © January 2019
Slide 18: JTX-8064: LILRB2 Inhibitor
JTX-8064: LILRB2* Inhibitor Highly Selective Monoclonal Antibody Reprograms Human Macrophages to Anti-Tumor Phenotype Pro-Inflammatory Anti-Inflammatory • TNFa • CCL2 • IL-6 • IL-10 JTX-8064 promotes M1-like activation JTX-8064 attenuates M2-like activation 1 0 0 0 0 1 0 0 0 0 8 0 0 0 d 8 0 0 0 d e
Slide 19: Deletion of PirB (LILRB2 Analog) Results in Anti-Tumor Activity
Deletion of PirB (LILRB2 Analog) Results in Anti-Tumor Activity Mouse expressing normal PirB target Mouse lacking PirB target MC38 tumor (macrophage staining) W T M C 3 8 P ir B M C 3 8 3 5 0 0 3 5 0 0 ) ) 3 3 3 0 0 0 3 0 0 0 m m m m 2 5 0 0 ( 2 5 0 0 ( e e m 2 0 0 0 2 0 0 0 m u u l l o 1 5 0 0 o 1
Slide 20: Development Programs: JTX-4014
Development Programs JTX-2011 JTX-8064 JTX-4014
Slide 21: JTX-4014: PD-1i Program On Track
JTX-4014: PD-1i Program On Track • IND filed Sept 2018 • Enrollment in first cohort completed • Establish safety and RP2D in 2019 Well-characterized PD-1 antibody Objective: Monotherapy safety & POC • Fully human IgG4 • For use in combinations with potential • Blocks binding to PD-L1 and PD-L2 futur
Slide 22: Delivering Value
DELIVERING VALUE PIPELINE EXECUTION APPROACH & IO OPPORTUNITY 22 | Jounce Therapeutics © January 2019
Slide 23: 2018 Accomplishments and 2019 Upcoming Milestones
2018 Accomplishments and 2019 Upcoming Milestones 2018 2019 ✓ Reported JTX-2011 preliminary clinical ▪ Three immunotherapies in the clinic efficacy results in Q2 ▪ JTX-2011: Data update including PFS ✓ Initiated new JTX-2011 combination and OS from ICONIC in 1H (CTLA-4i) ▪ JTX-2011: Initiate new Pha
Slide 24: Financial Strength and Flexibility
Financial Strength and Flexibility Company History • Strong balance sheet: – ~$215M cash and investments, Event Date Gross $ Comment as of September 30, 2018 Series A 2013 $47M Third Rock • Financial guidance: Ventures – End 2018 with $185M - $195M in cash Series B 2015 $56M Fidelity, – 2019 cash bu
Slide 25: Jounce Therapeutics: A Next Gen Immunotherapy Company
Jounce Therapeutics A Next Gen Immunotherapy Company
Jounce Therapeutics — Investor Presentation (January 2019) on 6ix